IHI publishes the draft topics ahead of the call launch to give applicants extra time to start networking and preparing a proposal.

The summit explored the challenges and opportunities in regulatory science that could be best addressed by a cross-sectoral, public-private partnership like IHI

The results of a new study, published in Nature Medicine, could make life easier for people taking part in clinical trials by reducing visits to a clinic for in-person assessments.

The Innovative Medicines Initiative’s AMR Accelerator is a proven model for the development of new antimicrobial drugs, experts say.

The VAC2VAC project provided vital evidence to demonstrate that non-animal alternatives can reliably detect certain contaminants in medicines administered by injection

Health research collaborations mean sharing data – we can deliver faster if we identify and remove obstacles early, write IHI's Niklas Blomberg and EFPIA's Magda Chlebus.

Setting up a non-profit association is one way to ensure the sustainability of EU-funded project results. Two Innovative Medicines Initiative projects share their experiences as they navigate this process.

A new clinical trial testing the best administration route for an experimental arthritis treatment is using outcome measures established by IMI project RT-Cure to evaluate its performance.

A nasal vaccine against pertussis that was tested using a model and cell bank created by IMI project PERISCOPE is entering the final phases of clinical trials.

The Innovative Medicines Initiative project published a series of recommendations for how the regulatory process in the EU for approving cell and gene therapies could be sped up